Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

C. M. Camaggi, E. Strocchi, A. Martoni, C. Zamagni, N. Cacciari, G. Robustelli della Cuna, L. Pavesi, M. Tedeschi, A. Silva, F. Pannuti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

Original languageEnglish
Pages (from-to)356-359
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume36
Issue number4
DOIs
Publication statusPublished - Jul 1995

Fingerprint

Megestrol Acetate
Pharmacokinetics
Tablets
Therapeutic Equivalency
Drug Compounding
Cross-Over Studies
Biological Availability
Labels
Neoplasms
Confidence Intervals
Plasmas
Pharmaceutical Chemistry

Keywords

  • Bioequivalence
  • Megestrol acetate
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Camaggi, C. M., Strocchi, E., Martoni, A., Zamagni, C., Cacciari, N., Robustelli della Cuna, G., ... Pannuti, F. (1995). Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 36(4), 356-359. https://doi.org/10.1007/BF00689055

Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies. / Camaggi, C. M.; Strocchi, E.; Martoni, A.; Zamagni, C.; Cacciari, N.; Robustelli della Cuna, G.; Pavesi, L.; Tedeschi, M.; Silva, A.; Pannuti, F.

In: Cancer Chemotherapy and Pharmacology, Vol. 36, No. 4, 07.1995, p. 356-359.

Research output: Contribution to journalArticle

Camaggi, CM, Strocchi, E, Martoni, A, Zamagni, C, Cacciari, N, Robustelli della Cuna, G, Pavesi, L, Tedeschi, M, Silva, A & Pannuti, F 1995, 'Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies', Cancer Chemotherapy and Pharmacology, vol. 36, no. 4, pp. 356-359. https://doi.org/10.1007/BF00689055
Camaggi, C. M. ; Strocchi, E. ; Martoni, A. ; Zamagni, C. ; Cacciari, N. ; Robustelli della Cuna, G. ; Pavesi, L. ; Tedeschi, M. ; Silva, A. ; Pannuti, F. / Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies. In: Cancer Chemotherapy and Pharmacology. 1995 ; Vol. 36, No. 4. pp. 356-359.
@article{931dd2e8f63b471c8c2312b9d44f1907,
title = "Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies",
abstract = "The bioequivalence of two megestrol acetate formulations, 160-mg {"}tablets{"} and 160-mg {"}sachets{"}, was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90{\%} confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.",
keywords = "Bioequivalence, Megestrol acetate, Pharmacokinetics",
author = "Camaggi, {C. M.} and E. Strocchi and A. Martoni and C. Zamagni and N. Cacciari and {Robustelli della Cuna}, G. and L. Pavesi and M. Tedeschi and A. Silva and F. Pannuti",
year = "1995",
month = "7",
doi = "10.1007/BF00689055",
language = "English",
volume = "36",
pages = "356--359",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

AU - Camaggi, C. M.

AU - Strocchi, E.

AU - Martoni, A.

AU - Zamagni, C.

AU - Cacciari, N.

AU - Robustelli della Cuna, G.

AU - Pavesi, L.

AU - Tedeschi, M.

AU - Silva, A.

AU - Pannuti, F.

PY - 1995/7

Y1 - 1995/7

N2 - The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

AB - The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

KW - Bioequivalence

KW - Megestrol acetate

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0029019018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029019018&partnerID=8YFLogxK

U2 - 10.1007/BF00689055

DO - 10.1007/BF00689055

M3 - Article

VL - 36

SP - 356

EP - 359

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -